Proteomic analysis of bladder cancer indicates Prx-I as a key molecule in BI-TK/GCV treatment system

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The Bifidobacterium infantis thymidine kinase/nucleoside analogue ganciclovir (BI-TK/GCV) system demonstrates anti-tumor activity in bladder cancer.
• Understanding the molecular underpinnings of this therapeutic system is crucial for optimizing bladder cancer treatment.

Purpose of the Study:

• To elucidate the molecular mechanisms of the BI-TK/GCV system in bladder cancer.
• To identify key proteins and signaling pathways affected by the BI-TK/GCV treatment.

Main Methods:

• Proteomic analysis using isobaric tags for relative and absolute quantification (iTRAQ) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS).
• Western blot and immunohistochemistry to validate protein expression changes.
• Gene silencing (shRNA) to investigate the role of Peroxiredoxin-I (Prx-I).
• Ingenuity Pathway Analysis (IPA) for signaling pathway identification.

Main Results:

• Treatment with the BI-TK/GCV system resulted in the differential expression of 192 down-regulated and 210 up-regulated proteins in Sprague-Dawley rats.
• Peroxiredoxin-I (Prx-I) was significantly down-regulated in bladder cancer post-treatment.
• Silencing of Prx-I suppressed tumor growth, induced apoptosis, and regulated the cell cycle in T24 bladder cancer cells.
• Prx-I silencing reduced phospho-NF-κB p50 and p65 expression, indicating a link to the NF-κB signaling pathway.

Conclusions:

• The BI-TK/GCV system exerts anti-tumor effects in bladder cancer through the down-regulation of Prx-I.
• Prx-I is identified as a potential therapeutic target for bladder cancer.
• The NF-κB signaling pathway is implicated in the mechanism of action of the BI-TK/GCV system via Prx-I modulation.